Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Inhibitor clinical burden of disease: a comparative analysis of the CHESS data

Authors: Abiola O. Oladapo, Mei Lu, Shaun Walsh, Jamie O’Hara, Teresa L. Kauf

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Patients with hemophilia and inhibitors generally face greater disease burden compared to patients without inhibitors. While raising awareness of relative burden may improve the standard of care for patients with inhibitors, comparative data are sparse. Analyzing data drawn from the Cost of Haemophilia across Europe – a Socioeconomic Survey (CHESS) study, the aim of this study was to compare the clinical burden of disease in patients with severe hemophilia with and without inhibitors. Hemophilia specialists (N = 139) across five European countries completed an online survey between January–April 2015, providing demographic, clinical and 12-month ambulatory/secondary care activity data for 1285 patients. Patients with hemophilia who currently presented with inhibitors and those who never had inhibitors were matched on baseline characteristics via propensity score matching. Outcomes were compared between the two cohorts using a paired t-test or Wilcoxon signed-rank or McNemar’s test.

Results

The proportion of patients who currently presented with inhibitors was 4.5% (58/1285). Compared to PS-matched patients without inhibitors, patients with inhibitors experienced more than twice the mean annual number of bleeds (mean ± standard deviation, 8.29 ± 9.18 vs 3.72 ± 3.95; p < .0001) and joint bleeds (2.17 ± 1.90 vs 0.98 ± 1.15; p < .0001), and required more hemophilia-related (mean ± standard deviation, 1.79 ± 1.83 vs 0.64 ± 1.13) and bleed-related hospitalizations (1.86 ± 1.88 vs 0.81 ± 1.26), hemophilia-related consultations (9.30 ± 4.99 vs 6.77 ± 4.47), and outpatient visits (22.09 ± 17.77 vs 11.48 ± 16.00) (all, p < .001). More than one-half (53.5%) experienced moderate/severe pain necessitating medication compared to one-third (32.8%) of patients without inhibitors (p = .01).

Conclusions

Patients with hemophilia and inhibitors exhibited greater clinical burden and higher resource utilization compared to their peers without inhibitors. Strategies for improving the standard of care may alleviate burden in this population.
Appendix
Available only for authorised users
Literature
1.
Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9.CrossRef
2.
Skinner MW. WFH: closing the global gap--achieving optimal care. Haemophilia. 2012;18(Suppl 4):1–12.CrossRef
3.
4.
Young G. From boy to man: recommendations for the transition process in haemophilia. Haemophilia. 2012;18(Suppl 5):27–32.CrossRef
5.
Brown SA, Aledort LM. Economic challenges in haemophilia. Haemophilia. 2005;11(1):64–72.CrossRef
6.
Globe DR, Cunningham WE, Andersen R, Dietrich SL, Curtis RG, Parish KL, et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia. 2003;9(3):325–31.CrossRef
7.
Shapiro AD, Donfield SM, Lynn HS, Cool VA, Stehbens JA, Hunsberger SL, et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics. 2001;108(6):E105.CrossRef
8.
Carazza M, Kodra Y, Armeni P, De Santis M, Lopez-Bastida J, Linertova R, et al. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):S53–65.
9.
Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25–32.CrossRef
10.
Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700–10.CrossRef
11.
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44.CrossRef
12.
Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11(6):1119–27.CrossRef
13.
Tagliaferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrera DB, et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost. 2015;114(1):35–45.CrossRef
14.
Oladapo AO, Epstein JD, Williams E, Ito D, Gringeri A, Valentino LA. Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials. Haemophilia. 2015;21(5):e344–58.CrossRef
15.
Morfini M, Haya S, Tagariello G, Pollmann H, Quintana M, Siegmund B, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13(5):606–12.CrossRef
16.
17.
Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904–13.CrossRef
18.
Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365(18):1684–92.CrossRef
19.
Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20(1):65–72.CrossRef
20.
Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008;14(3):466–75.CrossRef
21.
Gringeri A, Leissinger C, Cortesi PA, Jo H, Fusco F, Riva S, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia. 2013;19(5):736–43.CrossRef
22.
Stasyshyn O, Antunes SV, Mamonov V, Ye X, Epstein JD, Xiong Y, et al. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF prophylaxis study. Haemophilia. 2014;20(5):644–50.CrossRef
23.
Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia. 2012;18(3):e140–53.CrossRef
24.
Carcao M, Avila L, Blanchette VS, Santagostino E, Escuriola-Ettingshausen C, Leissinger CA, et al. Hemophilia prophylaxis no longer just for children without inhibitors - increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors). Blood. 2015;126:3535.
25.
Carcao M, Avila L, Aledort LM, Leissinger C. Prophylaxis practices in children and adults with hemophilia A or B and inhibitors. J Thromb Haemost. 2015;13:360.
26.
Walsh CE, Soucie JM, Miller CH. United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400–5.CrossRef
27.
28.
Young G. New challenges in hemophilia: long-term outcomes and complications. ASH Hematol. 2012;1:362–8.
29.
Leissinger C. Advances in the clinical management of inhibitors in hemophilia A and B. Sem Hematol. 2016;53:20–7.CrossRef
30.
Diamondstone LS, Aledort LM, Goedert JJ. Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders. Haemophilia. 2002;8(5):660–7.CrossRef
31.
Walsh CE, Soucie JM, Miller CH. Impact of inhibitors in hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400–5.CrossRef
32.
Tunstall O, Astermark J. Strategies for reducing inhibitor formation in severe haemophilia. Eur J Haematol. 2015;94(Suppl 77):45–50.CrossRef
33.
Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72.CrossRef
34.
Berntorp E, Mauser-Bunschoten E, Jimenez-Yuste V, Spears JB. Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies. Eur J Haematol. 2015;95(Suppl 80):1–15.PubMed
35.
Pocoski J, Ma A, Kessler M, Boklage S, Humphries TJ. Cardiovascular comorbidities are increased in US patients with haemophilia A: a retrospective database analysis. Haemophilia. 2014;20:472–8.CrossRef
36.
Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, et al. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia. 2012;18(1):39–45.CrossRef
37.
Schutgens RE, Klamroth R, Pabinger I, Malerba M, Dolan G. Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe. Haemophilia. 2014;20(5):682–6.CrossRef
38.
Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia. 2006;12(2):154–62.CrossRef
39.
Gringeri A, Mantovani LG, Scalone L, Mannucci PM, COCIS Study Group: Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003;102:2358–63.CrossRef
Metadata
Title
Inhibitor clinical burden of disease: a comparative analysis of the CHESS data
Authors
Abiola O. Oladapo
Mei Lu
Shaun Walsh
Jamie O’Hara
Teresa L. Kauf
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0929-9

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue

Research

6-minute walk test as a measure of disease progression and fatigability in a cohort of individuals with RYR1-related myopathies

Research

Hypermanganesemia due to mutations in SLC39A14: further insights into Mn deposition in the central nervous system

Research

Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study

Research

Decreased outlet angle of the superior cerebellar artery as indicator for dolichoectasia in late onset Pompe disease

Research

Comorbidity among HHT patients and their controls in a 20 years follow-up period

Research

Arginine does not rescue p.Q188R mutation deleterious effect in classic galactosemia